Latest Content

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

ADVI's Tyler Seville on how 340B has become a financial liability for manufacturers while covered entities expand into wealthy suburban markets.

Mereo BioPharma licenses its lung disease treatment alvelestat to Sentynl Therapeutics, Krieger Scientific's Joseph Morwald examines what's driving a surge in FDA warning letters, and IQVIA's Christopher Wooden and Tom Woods make the case for persona-based HCP engagement.

Why pricing pressure, policy volatility and supply-chain risk are pushing drugmakers toward greater cost and portfolio discipline, without losing sight of investment in innovation.

Overcoming the limits of traditional segmentation through a more connected, responsive and effective approach to health care professional engagement.

Mereo BioPharma has granted Sentynl Therapeutics an exclusive option to commercialize alvelestat in the U.S. for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease.

ADVI's Tyler Seville on how 340B grew from under $10 billion to over $100 billion annually — now larger than Medicaid and Medicare Part B.

Krieger Scientific’s founder and CEO discusses how various factors, such as siloed systems and misuse of AI, may be responsible for the increase of warning letters from FDA.

Renewal of FDA's Priority Review Voucher program is driving a rebound in U.S. rare disease biotech investment, while the UK continues to lag.

Why the industry must abandon its traditional top-down communications model and instead build trust through credible individuals, audience information habits and faster engagement in the peer-driven networks where health conversations now unfold.

President Trump signs an executive order shrinking the recommended childhood vaccine schedule from 18 diseases to 11, and calls for the MMR shot to be split into three separate injections.

BeOne Medicines and Revolution Medicines enter a two-part deal pairing BeOne's PRMT5 inhibitor and EGFR×MET trispecific antibody with Revolution's four clinical RAS(ON) inhibitors.